Visugen (Visoluten): The Retinal Khavinson Bioregulator — Research Overview

Introduction to Visugen

Visugen, commonly known as Visoluten or under the classification A-11, is a tissue-specific peptide bioregulator developed by Professor Vladimir Khavinson and his research team at the St. Petersburg Institute of Bioregulation and Gerontology. Unlike single-sequence synthetic peptides, Visugen is a complex preparation of short-chain amino acid sequences derived from retinal tissue of young animals, making it part of the broader class of Khavinson bioregulatory peptides.

The peptide complex carries a molecular weight up to 10 kDa and consists of multiple peptide fractions rather than a single defined amino acid sequence. This multi-component structure distinguishes Khavinson bioregulators from conventional targeted therapies and reflects the institute's research approach of identifying minimal peptide sequences from tissue extracts responsible for biological activity.

Tissue Target & Retinal Specificity

Visugen targets the retina, the light-sensitive tissue at the back of the eye responsible for photoreception and visual signal transduction. The bioregulator's design reflects decades of research into tissue-specific regulation: the short peptides in the Visugen complex are proposed to preferentially interact with retinal cells, modulating protein synthesis, cell proliferation, and apoptosis within the retina.

Retinal tissue undergoes age-related decline characterized by reduced cellular regeneration, accumulated oxidative stress, and declining protein synthesis capacity. Khavinson's hypothesis is that Visugen peptides can restore youthful gene expression patterns in retinal cells through epigenetic mechanisms, thereby supporting retinal structure and function.

Proposed Mechanism of Action

Khavinson bioregulators operate through a mechanism distinct from receptor-mediated signaling. Rather than binding to cell-surface receptors, these short peptides are proposed to:

• Cross Cell Membranes: The brevity and charge characteristics of Khavinson peptides are theorized to enable penetration across cell membranes without requiring conventional uptake mechanisms.
• Direct DNA Interaction: Once inside the cell nucleus, the peptides are proposed to interact directly with DNA, specifically with gene promoter regions controlling retinal gene expression.
• Restore Transcription Patterns: By modifying chromatin structure and gene accessibility, the peptides are theorized to restore youthful transcription profiles in aging retinal cells.
• Tissue-Specific Targeting: The specific amino acid composition of Visugen makes it preferentially active in retinal tissue, with lower activity in non-target tissues.

This epigenetic hypothesis distinguishes Khavinson's approach from conventional pharmacology and remains a subject of ongoing research and debate within the scientific community.

Published Research on Retinal Peptides

The Khavinson research program has produced multiple peer-reviewed publications examining retinal peptides and related bioregulators:

• Diabetic Retinopathy Study (PMID: 11521426): Research by Trofimova and Khavinson found that peptide bioregulators promoted improvement of vision acuity in 90% of patients studied and improved ophthalmoscopic findings, including resolution of hemorrhages and decreased macular edema in diabetic retinopathy cases.
• Retinitis Pigmentosa Research (PMID: 25272779): This publication examined molecular-physiological aspects of peptide regulation in retinitis pigmentosa, a progressive retinal degeneration condition. The study found that peptide bioregulators promoted restoration of physiological retinal activity in older adults and in animal models of the disease.
• Peptide Bioregulators Review (PMID: 24003726): A comprehensive review by Khavinson and colleagues summarized clinical efficacy results of peptide bioregulators (including retinal peptides like Retinalamin) for prevention and treatment across different age groups, emphasizing the long-term safety and efficacy data accumulated over 35+ years of research.
• Peptide Bioregulation of Aging (PMID: 19830585): A broader review examining how tissue-specific peptides like retinal bioregulators fit into the overall framework of peptide-based approaches to aging, discussing mechanisms and clinical applications.

Comparison with Other Vision-Related Peptides

Visugen occupies a unique niche among peptides studied for vision support:

• vs. Lutein & Zeaxanthin: These carotenoids are well-established antioxidant nutrients for retinal health; Visugen's mechanism (epigenetic gene regulation) is distinct from simple antioxidant activity.
• vs. Nerve Growth Factor (NGF): NGF is a longer-chain growth factor being studied for neuroprotection; Visugen's ultra-short peptide approach and proposed DNA-interaction mechanism differ fundamentally.
• vs. Other Khavinson Bioregulators: Visugen (A-11, retinal) differs from testicular peptides (A-5), cartilage peptides (A-4), and other tissue-specific bioregulators by its specific tissue targeting and corresponding mechanism within retinal cells.

Research Context & Historical Development

Visugen's development reflects 40+ years of systematic research at the St. Petersburg Institute of Bioregulation and Gerontology. The institute was originally established under Soviet auspices as the Institute of Military Medicine, focusing on polypeptide-rich fractions from animal organs. Following the Soviet Union's collapse, the research program continued as an independent institute under the Russian Academy of Medical Sciences.

The shift toward tissue-specific short-chain peptides emerged from systematic analysis of organ extracts: researchers identified the minimal peptide sequences responsible for biological effects, then synthesized these short sequences (typically 2–4 amino acids) to create defined bioregulatory compounds. This approach yielded a family of tissue-specific peptides, with Visugen representing the retinal member of this family.

By 2025, the Khavinson research program had generated 775+ peer-reviewed publications in journals including Bulletin of Experimental Biology and Medicine, Biogerontology, and Advances in Gerontology, establishing a substantial literature on tissue-specific peptide bioregulation.

Current Research Directions

Ongoing research on retinal Khavinson peptides focuses on:

• Detailed molecular mechanisms of peptide-DNA interaction and epigenetic regulation in retinal cells.
• Clinical efficacy in age-related macular degeneration (AMD), beyond the diabetic retinopathy and retinitis pigmentosa studies cited above.
• Synergistic effects when combined with other neuroprotective compounds.
• Pharmacokinetics and bioavailability optimization in different delivery formats.

Disclaimer

These peptides are for research purposes only and are not approved for human use. This article is educational and summarizes published research on Khavinson bioregulators. Visugen/Visoluten is not an FDA-approved medication in the United States and should not be used for self-treatment of any medical condition. Readers interested in retinal health should consult qualified healthcare providers and ophthalmologists. Any research use of Visugen must comply with local regulations and institutional review board approval where required.